Correlation Between Halozyme Therapeutics and Ultragenyx

Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Halozyme Therapeutics and Ultragenyx, you can compare the effects of market volatilities on Halozyme Therapeutics and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Ultragenyx.

Diversification Opportunities for Halozyme Therapeutics and Ultragenyx

0.65

Correlation Coefficient

Halozyme Therapeutics  Ultragenyx

Poor diversification

The 3 months correlation between Halozyme and Ultragenyx is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Ultragenyx go up and down completely randomly.

Pair Corralation between Halozyme Therapeutics and Ultragenyx

Given the investment horizon of 90 days Halozyme Therapeutics is expected to under-perform the Ultragenyx. In addition to that, Halozyme Therapeutics is 1.91 times more volatile than Ultragenyx. It trades about -0.07 of its total potential returns per unit of risk. Ultragenyx is currently generating about -0.12 per unit of volatility. If you would invest  5,783  in Ultragenyx on September 12, 2024 and sell it today you would lose (874.00) from holding Ultragenyx or give up 15.11% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Halozyme Therapeutics  vs.  Ultragenyx

Halozyme Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Halozyme Therapeutics and Ultragenyx

The main advantage of trading using opposite Halozyme Therapeutics and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.

The idea behind Halozyme Therapeutics and Ultragenyx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.